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Abstract
Small non-coding RNAs (sncRNAs) are small regulatory molecules, which play key 
roles in fine-tune of all cell functions. In late 1970s and early 1980s, it was first deter-
mined that non-coding RNAs contribute to the cellular regulatory processes. The king-
dom of sncRNAs is very numerous and it is clear that functions of different members of 
this family is different from each other and may be involved in normal and pathologic 
processes in cell. Recently it was investigated that sncRNAs and long non-coding RNAs 
play roles in cellular differentiation, proliferation, metabolic processes, bioenergetic 
regulation, cell death and inter-cellular communications, etc. In embryos, non-coding 
RNAs control maternal-zygotic transition, the maintenance of pluripotency, the patter-
ing of the body axes, the specification and differentiation of cell types and morpho-
genesis of organs. Development of hematologic malignancies in humans, their course 
and regulation of resistance and sensitivity of tumorous cells to therapy are under the 
control of sncRNAs.
Keywords: small non-coding RNAs, micro-RNAs, antago-miRNA, nano-sized polymer 
carriers, leukemic cell transformation
1. Introduction
1.1. Small non-coding RNAs
Small non-coding RNAs (sncRNAs) are oligonucleotides with length less than 200 nt. This 
is numerous family of non-coding genomic regulators. The most investigated sncRNAs are 
micro-RNAs (miRNAs) and small interfered RNAs (siRNAs). Less studied sncRNAs are 
piwi-interacting RNAs (piRNAs), small nuclear RNAs (snRNAs) and small nucleolar RNAs 
(snoRNAs) [1, 2].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1.2. Biogenesis of micro-RNAs and piwi-interacting RNAs
All small non-coding RNAs before they become functionally active undergo different pro-
cesses of biogenesis from their precursor form. This multistep maturation is necessary 
for normal functionality of small non-coding RNAs. Imbalance of one or more steps of 
sncRNAs biogenesis may results in development of different pathologic disorders and car-
cinogenesis [3].
1.3. micro-RNAs
miRNAs are small, single-stranded RNAs (ssRNAs) that are less than 24 nucleotides in 
length. They control translation of more than 60% of protein-coding genes. Four different 
mechanisms of regulation exist: inhibition of translation initiation, suppression of transla-
tion elongation, degradation of co-translational protein and initiation of translation termi-
nation [4–8].
The biogenesis of miRNAs was previously described [9–13]. Primary miRNAs (pri-miR-
NAs) are mostly transcribed by RNA Polymerase II (RNA Pol II). After that, pri-miRNAs 
undergo nuclear processing by the microprocessor complex of RNAse III enzyme Drosha/
DGCR8 (DiGeorge syndrome critical region gene 8), followed by export into the cytoplasm 
as pre-miRNAs complexed with exportin5 and RAN GTP [9–11]. In the cytoplasm, immature 
miRNAs are duplexes by the cytoplasmic RNase III Dicer together with its catalytic part-
ner Trans-activator RNA (tar)-binding protein (TRBP). Dicer/TRBP cleavage pre-miRNAs 
in duplex RNA (dsRNA) is loaded onto Argonaute (AGO) proteins to generate the RNA-
induced silencing complex (RISC). RISC contains a single-stranded miRNAs and guide them 
to theirs target mRNAs [12, 13].
1.4. Piwi-interacting RNAs
PiRNAs, 26–32 nt long small non-coding RNAs that are associated with the piwi-class AGO 
protein family, are generated independently of Dicer from single-stranded precursors [14]. 
The primary function of these sncRNAs is silencing of transposable elements through de 
novo DNA methylation [15]. Some piRNAs are silencing target protein-coding genes [16]. 
Recently two models of piRNA biogenesis were proposed: the primary processing and the 
secondary amplification (ping-pong amplification loop) pathways. In the germline, piRNA 
biogenesis involves both pathways. Two putative RNA helicases, Armi and FS(1)Yb (Female 
Sterile (1) Yb; also known as Yb) and a nuclease, Zuc (Zucchini), as factors of primary piRNA 
biogenesis. PiRNA precursors or intermediates obtained from uni-strand clusters are cut 
by Zuc to produce piRNAs that bind to piwi proteins. Amplification of loop pathway is 
activated by piRNA derived from primary biogenesis pathway. There should be a relative 
increase in abundance of complementary piRNAs due to the amplification. The primary pool 
of piRNAs amplifying sequences is silencing active transposons in the secondary ping-pong 
amplification loops cycles. The ping-pong amplification loop characterized in many animal 
species requires piwi subfamily proteins: piwi and Aub [17–19]. Sense-strand piRNAs react 
with Ago3 [20], whereas antisense piRNAs bound to Piwi or Aub [21]. In the ping-pong 
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amplification loop model of piRNA biogenesis, antisense piRNAs in complex with Aub 
directly cleaves sense-strand transposon sequences, generating sense piRNAs for Ago3. The 
Ago3-piRNA complex then directs cleavage of antisense piRNA precursors, generating anti-
sense piRNAs for Aub. The 5′-ends of amplified secondary piRNAs are determined by Aub 
and Ago3 Slicer [22–25].
1.5. Role of sncRNAs in carcinogenesis
sncRNAs may play double-faced roles in carcinogenesis as oncogenes and tumor suppres-
sors. As oncogenes sncRNAs function in tumor initiation, progression and resistance to thera-
pies; as tumor suppressors, sncRNAs inhibit cell growth, induce apoptosis, block cell cycle 
and promote cell differentiation [26, 27]. In every pathologic condition, its own biomarker 
sncRNAs exist which indicate prognosis, course of disease and resistance or sensitivity to 
ongoing treatment. These biomarkers may be a basis for creation of new drugs for epigenetic 
therapy of cancers.
2. sncRNAs in AML
In acute myeloid leukemia (AML), some sncRNAs may play roles in oncogenes and other 
sncRNAs may be tumor suppressors. Oncogenic sncRNAs are miRNA-155, miRNA-17-92 
cluster, miRNA-221, miRNA-21, etc. Tumor suppressive functions have miRNA-15a/16 clus-
ter, miRNA-29b, miRNA-181b and members of let-7 cluster [28]. These sncRNAs may be deter-
mined as biomarkers and prognostic markers in AML.
2.1. sncRNAs as biomarkers and prognostic markers of AML
Acute myeloid leukemia (AML) is a heterogeneous hematologic disease, which characterizes 
with disturbances of differentiation and maturation of hematopoietic stem cells or progenitor 
cells and appearance of immature blasts in periphery blood. Any classifications of AML are 
existing (WHO, 2008 with corrections in 2016) [29]. Classification of AML in dependence of 
genetic abnormalities is one of the basic classifications for this disease. All genetic changes in 
AML are also associated with imbalance of expression of different sncRNAs. These sncRNAs 
can be determined as biomarkers of particular type of AML. In Table 1, presents the most 
comprehensive analysis of dysregulated sncRNAs in dependence of AML type. All displayed 
sncRNAs profiles were taken from clinical investigations in AML patients.
2.2. Role of separated miRNAs and piRNAs in AML
miRNA, which most often involved in pathologic processes in AML are let-7 family of miR-
NAs, miRNA-16, 17–92 cluster, miRNA-29, miRNA-30, miRNA-146, miRNA-150, miRNA-155, 
miRNA-196 and miRNA-223. The oncogenic markers are miRNA-17-92 cluster, miRNA-155 
and miRNA-196; the tumor suppressive are miRNA-15/16, let-7 family, miRNA-29, miRNA-
30, miRNA-146, miRNA-150 and miRNA-223 (Figure 1).
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Let-7. The let-7 is a 13-member family of miRNAs expressed in human tissues. This sncRNAs 
are induced in embryogenesis and then its high levels are detected in different tissues. Down-
expression of let-7 was obtained in early embryogenesis and its suppression was observed in 
many types of cancers. The main functions of let-7 miRNA are tumor suppression and sup-
porting of cell differentiation. Let-7 targets a human rat sarcoma (RAS) ortholog, a high-mobil-
ity group AT-hook 2 (HMGA2) and MYC. These factors are human oncogenes. Let-7 regulates 
Type of AML [29, 32] Downregulated Upregulated
AML with t(8;21)(q22;q22.1); 
RUNX1-RUNX1T1
miRNA-9, 18a, 19a–b, 20a, 92, 193a, 196 [34]; 
miRNA-196b [36]; 21, 26a, 125a, 142-3p, 196a, 
494 [37]; 133, 17-3p, 17-5p [38]; let-7b, c [40]
miRNA-126, 130 [33, 36]; let-7a-3, 
30a, b, c [34]; 27a, 146a, b, 150, 155, 
181a, b, 223 [37]; 17–92, miRNA-
24a, b [40]
AML with inv.(16)
(p13.1q22) or t(16;16)
(p13.1;q22); CBFB-MYH11
miRNA-30b, d, 335 [36]; 196a, b [37]; let-7b, c [40] miRNA-126 [36]; 126 [40]
AML with t(9;11)
(p21.3;q23.3); 
MLLT3-KMT2A
miRNA-22, 24, 29a, b, 30a, 124, 132, 133a, 133b, 
146a, b, 150, 155, 193b, 221, 222, 424, 503, 542 
[33]; 23a, 181b, 210, 495 [34, 35]; let-7c, miRNA-
26a, 30c, d, 100, 125b, 126-3p, 143, 181a, d [37]; 
16, 29s, 34a [38]; let-7b, miRNA-29c [40]
Let-7a-3, miRNA-30a, b, c, 17h, g, 
196b, 328 [34, 35]; 21, 196a, b [37]; 
17–92, 196a, 219, 326 [38, 40]
APL (M3) with a 
translocation between 
chromosomes 15 and 17 
(PML-RARA)
Let-7c, miRNA-15b, 107, 143, 210, 223, 342 [33]; 
miRNA-16 [34]; 23a [35]; 485-5p [36]; let-7b, 18b, 
22, 24, 27a, 126-3p, 150, 196a, b, 378 [37]; 17-5p, 
20a [39]
Let-7a, let-7d, miRNA-142, 181b 
[33]; let-7a-3, miRNA-30a, b, c, 
337-3p [34]; 125b [35, 37]; 29a, 100, 
146a, 146b-5p, 181 a, b [37]; 127, 
299, 323, 368, 382 [38, 40]
AML with t(6;9)(p23;q34.1); 
DEK-NUP214
AML with inv.(3)
(q21.3q26.2) or t(3;3)
(q21.3;q26.2); GATA2, 
MECOM
miRNA-449a [35]
AML (megakaryoblastic) 
with t(1;22)(p13.3;q13.3); 
RBM15-MKL1
miRNA-29a [37] miRNA-335, miRNA-375 [37]
AML with BCR-ABL1 miRNA-203 [41]; 150 [42]; 451 [43]; 120, 151, 155, 
31, 564 [44];
miRNA-23a [41]; 125b, 96 [44];
AML with mutated NPM1 miRNA-424, 181a, b [46]; 320, 145, let-7c [47]; 
10b, let-7, miRNA-29, 181a, 124, 128, 194, 219, 
220a [48]; 204, 126, 130a, 451 [38]
miRNA-10a-5p [45]; 155 [46]; 196a, 
b [47]
AML with biallelic 
mutations of CEBPA
miRNA-34a [49] miRNA-328 [44]; miRNA-181a 
[38, 48]; 335 [38]
AML with mutated RUNX1 Let-7, miRNA-223, 99a, 100 [48] miRNA-24, 23, 27, 155, 211, 220, 
595 [48]
Table 1. AML with recurrent genetic abnormalities [30, 31].
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cell cycle suppression of any cyclins, such as cyclin A, cyclin D1 and cyclin-dependent 
kinase 4 (CDK4). It may indirectly suppress LIN28 by the direct inhibition of MYC [23, 24]. 
Let-7c induces megakaryocytic cell differentiation as the result of targeting of PBX2 in myeloid 
cells. This factor in cooperation with Meis1 and HoxA9 are required for MLL-dependent leu-
kemogenesis. Acute promyelocytic leukemia (APL) decreases let-7c levels and cooperation of 
KRAS with PML-RARA results in poor prognosis of disease [25, 26, 50, 51]. One more novel 
axis was determined in poor prognosis leukemia. This is protein tyrosine phosphatase of 
regenerating liver 3: PRL-3/LIN28B/let-7 axis. PRL-3 induces activation the PI3K/AKT path-
way and Src-ERK1/2 pathways. PRL-3 phosphatase activity upregulates LIN28B, a stem cell 
reprogramming factor, which in turn represses the let-7 mRNA family, inducing a stem cell-
like transcriptional program. These pathways support epithelial-mesenchymal transition and 
results in metastatic processes. PRL-3 is detected in more than 50% of patients with AML [27, 
52].
miRNA-16. miRNA-16 is tumor suppressor sncRNAs. miRNA-16 targets anti-apoptotic gene 
Bcl-2 (B-cell lymphoma 2) and numerous genes, which are involved in cell cycle regulation. 
Those genes are cyclin D1, D3, E1 and cyclin-dependent kinase 6 (CDK6). miRNA-16 regu-
lates genes supporting Wnt-signaling pathway, such as WNT3A (wingless-type MMTV inte-
gration site family, member 3A). As a result, miRNA-16 can fine-tune cell cycle, support cell 
apoptosis and inhibit cell proliferation [28, 53]. Erythropoiesis is supported by miRNA-16 and 
its expression positively correlates with the appearance of erythroid surface antigens (CD36, 
CD71 and CD235a) [29, 54]. Its level is downregulated in APL. After treatment, ATRA levels 
of miRNA-16 increase [26, 51].
miRNA-17-92. miRNA-17-92 is one of the most investigated oncogenic miRNA complex in 
leukemia. Cluster 17–92 is complex of seven co-operating miRNAs. Members of this clus-
ter are miRNA-17, miRNA-17*, miRNA-18a, miRNA-19a, miRNA-20a, miRNA-19b-1 and 
Normal cell Tumor cell
sncRNAs with 
tumor suppressive properties
Oncogenic sncRNAs
let-7 family
miRNA-16
miRNA-29
miRNA-30
miRNA-146
miRNA-150
miRNA-223
cell proliferation
metastatic activity
cell differentiation
cell apoptosis
miRNA-17-92 cluster
miRNA-155
miRNA-196
Figure 1. Influence of tumor suppressor sncRNAs and oncogenic sncRNAs on main functions of cells.
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miRNA-92a-1. These miRNAs are located at 13q31. The majority of miRNAs from this cluster 
are overexpressed in MLL-rearranged AML. These miRNAs can support cell proliferation, 
cell viability, inhibit apoptosis, suppress cell differentiation and induce malignant transfor-
mation. In normal hematopoiesis, this complex plays essential roles in monocytopoiesis and 
megakaryocytopoiesis. Targets for 17–92 complex are factors of cellular proliferation E2F1, 
E2F2, E2F3, PTEN (tumor suppressor phosphatase and tensin homolog), BIM (pro-apoptotic 
molecule), AML1, TGFBR2, NCOA3, RBL2, DOCK5, THBS1 and CTGF. RASSF2 and RB1 
genes are target genes in leukemia [29–33, 38, 54–57]. In vivo cluster 17–92 expression signifi-
cantly decreases leukemia latency [34, 40].
miRNA-29. The miRNAs-29 family consists of miRNA-29a, miRNA-29b and miRNA-29c, and 
is encoded and transcribed in tandem by two genes located on chromosome 7q32.3 (miRNA-
29a/b1 locus) or chromosome1q32.2 (miRNA-29a/b2 locus), respectively. As was shown 
recently, miRNA-29a and miRNA-29b regulate critical anti-apoptotic genes, such as myeloid 
cell leukemia-1 (MCL-1) and play tumor suppressor role. These results indicated that miRNA-
29a and miRNA-29b target Mcl-1 and play roles in regulation of apoptosis in AML. Bcl-2, 
Mcl-1 and Bcl-Xl are anti-apoptotic proteins and promote cell survival and proliferation. Both 
miRNA-29a and miRNA-29b not only directly target anti-apoptotic genes but also upregulate 
pro-apoptotic genes, such as BIM (BCL2L11), p53 and the tumor suppressor programmed cell 
death-4 (PDCD4) [35, 36, 58, 59]. Overexpression of miRNA-29a, miRNA-29b or miRNA-2c 
markedly inhibited cell proliferation and promoted cell apoptosis by targeting protein kinase 
B2 (AKT2) and cyclin D2 mRNAs.
miRNA-29b targets DNA methyltransferases (DNMTs) and downregulates DNA methylation 
in malignant cells. In AML cells, enhanced expression of miRNA-29b results in the reduction 
of the expression of DNMT1, DNMT3A and DNMT3B. miRNA-29b downregulates DNMT1 
indirectly by targeting Sp1, a trans-activator of the DNMT1 gene due to a decrease in global 
DNA methylation and re-expression of p15 (INK4b) and ESR1. Moreover, miRNA-29 family 
members may downregulate the active DNA demethylation pathway members tet-methylcy-
tosine dioxygenase (TET1) and thymine DNA glycosylase (TDG) [37, 60]. miRNA-29 targets 
CCNT2 that is a component of the positive transcription elongation factor b (P-TEFb). P-TEFb 
is essential for the elongation of transcription and co-transcriptional processing by RNA 
polymerase II. Different P-TEFb complexes can regulate subsets of distinct genes that are 
important for the embryonic development. miRNA-29 family miRNAs downregulate cyclin-
dependent kinase 6. It provides a differentiation promoting activity of Runx proteins to be 
selectively activated in terminally differentiating cells [38, 61].
miRNA-30. miRNA-30 as was shown is tumor suppressor miRNA in AML. miRNA-30 down-
regulates NOTCH1 gene expression to promote granulocytic differentiation [39, 62].
miRNA-146. miRNA-146a and miRNA-146b are two miRNA, which are highly expressed in 
primitive bone marrow cells (lineage negative). In mature blood cells, their expressions are 
different. miRNA-146a is highly expressed in blood cells maturation lineage. The expression 
of miRNA-146a is regulated by a combination of PU.1 (spleen focus-forming virus proviral 
integration 1) and c-ETS. It was supposed, that miRNA-146a controls maturation of blood 
marrow stem cells in adults and plays role in the self-renewal of long-term hematopoietic 
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stem cells. The decrease or deletion of miRNA-146 levels could result in development of 
AML in adults [40, 63]. miRNA-146a negatively regulates NF-kB by suppressing two signal 
transducers, TRAF6 (TNF receptor-associated factor 6) and IRAK1 (IL-1 receptor-associated 
kinase 1). Absence of miRNA-146a expression is due to NF-kB hyper-expression, which 
involves miRNA-146a/TRAF6/NF-kB/IL-6 pathway resulting in depletion of hematopoietic 
stem cells and the development of myeloproliferative diseases [41, 64]. miRNA-146a also 
downregulates CSF1R. Increased expression of this factor is strongly associated with the 
development of AML [42, 65]. Furthermore, high expression of miRNA-146a impaired bone 
marrow reconstitution in mice and reduced survival of hematopoietic stem cells. Treatment 
of AML patients with ATRA results in downregulation of miRNA-146a, which is associated 
with upregulation of Smad4 pathway [43, 66]. miRNA-146a is downregulated in MLL rear-
rangements. MLL-rearranged AML MEIS1 and HOXA9 are key target genes of MLL-fusion 
proteins. MEIS1/HOXA9 downregulate PU.1 expression, which is essential for miRNA-146a 
expression. Low levels of miRNA-146a result in high levels of SYK and its activation. SYK 
expression and activation is switch leukemic cellular transformation [44, 67].
miRNA-150. miRNA-150 is one of the main regulators of hematopoiesis. It is expressed in 
normal hematopoietic stem cells. The known target for miRNA-150 is Myb, which regulates 
differentiation of progenitor cells toward megakaryocytes and erythrocytes, supporting 
c-KIT expression. In majority of cases of patients with AML this miRNA is downregulated 
[45, 68]. Downregulation of miRNA-150 is associated with misbalance of regulatory fac-
tors. MLL-fusion proteins bind to the promoter regions of miRNA-150 and directly pro-
mote its expression, however, blocking maturation and biogenesis of this miRNA [46, 47, 
69, 70]. Repression of miRNA-150 maturation is associated with expression of Myc protein. 
Myc is a direct target for MLL-fusion protein, which binds to the promoter region of LIN28 
and activates its transcription [48, 71]. miRNA-150 is an important regulator of hemato-
poietic recovery after treatments with chemotherapeutic drugs. miRNA-150 targets other 
genes that are necessary for leukemogenesis. These genes are HOXA7, Meis1 and cyclin-
dependent kinase 2 [38, 72].
miRNA-155. miRNA-155 expressed in high levels in normal HSC and in low in mature hema-
topoietic precursors. It controls early maturation of HSC until common myeloid progenitor 
stage. miRNA-155 supports the leukemogenesis by downregulation of SH2 domain-con-
taining inositol 5′-phosphatase 1 (SHIP1) translation, activating SHIP1-mediated PI3K-Akt 
pathway. This event is due to myeloproliferation and decrease of erythropoiesis. SHIP1 
downregulation results in activation of IL-6 signaling pathway and induces a reactive pro-
liferation of the relatively apoptosis-resistant myeloid precursor cells [49, 73]. Key targets 
of miRNA-155 are PU.1 and Cebpb in myeloid progenitors. PU.1 transcriptionally activates 
miRNA-155, forming positive regulatory loop. PU.1 and CCAAT/enhancer-binding protein b 
(C/EBPb) transcriptionally regulate expression of myeloid-specific miRNA-223, which upreg-
ulates myelopoiesis by indirectly regulating C/EBPa [50, 51, 74, 75]. miRNA-155 promotes 
production of inflammatory cytokines in mature myeloid cells. It negatively regulates anti-
inflammatory factors, such as SHIP1 and SOCS1 [52, 76]. miRNA-155 reduces apoptotic activ 
ity of myeloid cells in vitro and in vivo by the regulation of Akt-signaling pathway [53, 54, 77, 78]. 
In silico target prediction identified a number of putative miRNA-155 target genes, and the 
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expression changes transcription factors of myeloid proliferation and apoptosis, such as 
MEIS1, GF1, cMYC JARID2, cJUN, FOS, CTNNB1 and TRIB2 [55, 79].
miRNA-196. miRNA-196 is a member of homebox regions (HOX) clusters family miRNAs: 
miRNA-10, 196 and 615. HOX genes encode transcription factors, which control embryonic 
development. miRNA-196 are highly expressed in AML. MLL-fusion proteins directly upregu-
late expression of miRNA-196, which is necessary for leukemic cells immortalization. miRNA-
196 blocks granulocyte colony-stimulating factor-induced granulopoiesis [56, 80]. Recently 
it determined double-faced regulation by the miRNA-196 of MLL-associated AML. miRNA-
196 may be double-faced Janus in MLL-rearranged AML. On the one hand, it targets MLL-
associated HOXA9/MEIS1 oncogenes; on the other hand, it regulates first apoptosis signal 
(FAS) (also known as Apo-1 or CD95) tumor suppressor gene. High expression of miRNA-196 
is associated with the more aggressive leukemic phenotypes and worse prognosis for patients 
with leukemia [38, 57, 81, 82].
miRNA-223. miRNA-223 is an intergenic miRNA, which is highly expressed in human periph-
eral blood granulocytes and bone marrow-committed myeloid precursors. It is regulated by two 
factors PU.1 and C/EBPb [40, 58, 59, 83–85]. miRNA-223 has tumor-suppressive role in AML, 
and its expression is downregulated in this disease. Targets for miRNA-223 are erythrocyte 
membrane protein band 4.1 like 3, septin 6, FBXW7, ataxia teleangiectasia mutated, insulin-like 
growth factor 1, paired box 6 and caprin-1. FBXW7 (F-box protein in the SCF E3 ligase complex) 
protein leads to ubiquitination of binding proteins and proteasomal degradation. It regulates 
cell proliferation, differentiation, cell cycle, migration and invasion. miRNA-223 downregu-
lates this factor and results in inhibition of cell proliferation and enhancing apoptosis [60, 86]. 
Other target genes for miRNA-223 are LMO2, NFI-A, MEF2C (myocyte enhancer factor) and 
E2F1 (adenovirus E2 promoter-binding factor 1). In normal conditions, increased expression 
of miRNA-223 promotes differentiation toward granulocytes. Its repression associated with 
differentiation to erythrocytes and monocytes/macrophages [40, 61, 83, 87]. C/EBPa regulates 
miRNA-223 that blocks myeloid cell cycle progression by targeting E2F1. Overexpression of 
E2F1 results in repression of miRNA-223 gene expression by the negative feedback [62, 88].
2.3. Piwi-interacting RNAs
Piwi-interacting RNAs is the most numerous class of sncRNAs, whose action in normal and 
malignant hematopoiesis is less studied. Piwi-regulatory proteins are Argonaute family pro-
teins, which are essential for germ stem cells self-renewal and maintenance. They are encoded 
by highly conserved PIWI genes. Human genome has four piwi-coding genes: HIWI, HILI, 
HIWI3 and HIWI2. Piwi proteins are associated with piRNAs and they act in cooperation 
with each other. Firstly, piwi proteins were identified in germ cells and then in somatic cells 
[63, 89]. A growing number of studies have found that piwi proteins in humans and mice, 
specifically, HIWI, PIWIL2 and PIWIL2-like proteins, are expressed in various types of tumor 
cells. In addition, piRNAs were also detected in these cells [64, 90].
In AML, piwi proteins and piRNAs are deregulated. Recently, it was shown that high expres-
sion of piwi-like protein 4 in leukemic cells in 72% of the patients with different types of AML 
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compared to healthy controls, and in 90% of the patients with MLL-AF9 rearranged AML [13, 
65]. PiRNAs act as sequence-specific guides for piwi proteins, and they support biogenesis 
and stability of piRNAs. Piwi and piRNAs are involved in the intra-nuclear processes such 
as heterochromatin formation, mobile transposable elements (TE) silencing and repressive 
histone modifications (H3K9me3). The piwi protein PIWIL4 is overexpressed in a large pro-
portion of AML leukemia patients. This knockdown results in gross changes in histone meth-
ylation and slowed leukemic growth. It suggests a tightly regulated piwi pathway is essential 
for normal hematopoiesis [66, 91].
Mobile transposable elements, which are under the control of piwi and piRNAs constitute 
approx. 44% of the human genome. TE could actively contribute to genetic heterogeneity, to 
alter the behavior during adaptation, and responses to stress. Somatic retrotransposition and 
its associated insertional mutagenesis have particularly important implications for carcino-
genesis and are often associated with different cancers. TE activity can generate a wide spec-
trum of genomic mutations, ranging from point mutations to gross rearrangements. These 
events may be due to development of different diseases. Mobile transposable elements such 
as duplications caused by Alu-Alu (SINE type of TEs) recombination in intron 1 and 6, result 
in a duplication of exons 2–6 of gene MLL1 [67, 68, 92, 93]. Chromosomal rearrangements in 
MLL are result of Alu recombination. In partial duplication events, TEs are inserted near the 
translocation breakpoints. MYB and MLL duplications were also obtained in healthy controls, 
whereas leukemogenesis is induced by TE insertions during blood cell differentiation [69, 94]. 
Knockdown of the murine piwi protein MIWI2 leads to abnormal hematopoiesis and ery 
throid precursors take on characteristics of more differentiated erythroid cells [70, 71, 95, 96]. 
The roles of piRNAs in hematopoiesis have only just begun to be explored and it seems likely 
that more will be uncovered in the near future. Certainly, regulation of mobile transposable 
elements, histone modificatiowns, DNA methylation processes by piwi and piRNAs are 
important for leukemogenesis and for tumor suppression. Investigation of new piwi/piR-
NAs biomarkers will be a novel diagnostic tool and possible hopeful epigenetic treatment of 
patients with AML in future.
2.4. SncRNAs as markers of therapeutic resistance or sensitivity to AML treatment
All sncRNAs from the view of chemoresistance and sensitivity of AML patients to the cur-
rent treatment can be assigned to the two groups. Group 1 characterized with high level of 
expression of sncRNAs, which associated with sensitivity to therapy. This group members are 
miRNA-181a, b; let-7f, miRNA-9*, miRNA-96, miRNA-135a, miRNA-409, miRNA-10, miRNA-
29b and miRNA-217 [72, 73, 97–100]. Group 1 members act through activation of cellular dif-
ferentiation, inhibition of leukemic cells proliferation and survival, regulation of cell cycle, 
inducing of apoptosis and suppression of migration and invasion. Group 2 characterized with 
high expression of sncRNAs, which associated with resistance to therapy. Group 2 members 
are miRNA-155, miRNA-125b, miRNA-126, miRNA-210, miRNA-3151, miRNA-196b, miRNA-
199a, miRNA-191, miRNA-644, miRNA-363, miRNA-532-5p and miRNA-342-3p [74, 101].
miRNA-181a is the most investigated miRNA with its chemosensitive action on leukemic 
cells. Investigations of samples from cohort of patients of different ages, miRNA-181a was 
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identified as marker of chemosensitivity [75, 102]. The main function of this miRNA is acti-
vation of apoptotic activity in cells and inducing sensitivity of leukemic to native immunity 
action. Direct targets for this miRNA are KRAS, NRAS, transcription factor Prospero home-
box protein 1 (Prox1) and HMGB1, a member of the high-mobility group box DNA-binding 
proteins. The CD4 co-receptor is another target for miRNA-181a. Anti-proliferative effect of 
miRNA-181a is associated with targeting of FBJ murine osteosarcoma viral oncogene homo-
log (FOS), which is involved in Moloney murine sarcoma viral oncogene homolog (MOS)/
dual specificity mitogen-activated protein kinase (MEK)/mitogen-activated protein kinase 
(ERK) pathway [76, 103]. miRNA-181a can sensitize leukemic cells to natural killer (NK) cell 
action [77, 104]. miRNA-181a regulates mechanisms of cell proliferation, differentiation and 
apoptosis of normal cells. All regulated targets for miRNA-181a are aberrantly expressed and 
are frequently mutated in acute myeloid leukemia. Promotion of high expression of miRNA-
181 in the case of AML may have partial positive effect for chemosensitivity of leukemic cells 
and for anti-leukemic activity [78, 79, 105, 106].
Other miRNA, which enhances chemosensitivity of leukemic cells is miRNA-217. This 
sncRNA decreases leukemic cell proliferation via the cell apoptosis pathway. It targets KRAS 
regulator of signaling links from extracellular space to the nucleus. KRAS connects multiple 
upstream signals to various downstream signaling pathways [97].
miRNA-155 is oncogenic miRNA, whose high expression is able increase chemoresistant 
effects of anti-leukemic drugs. Its increased expression is correlated with decreased CR rates 
and a shorter overall survival (OS) of patients with AML. In our laboratory, primary in vitro 
leukemic cells were transformed into megakaryocytes after using complexes of polymer car-
rier with antgo-miRNA-155 [80, 107].
Another miRNA from the second group is miRNA-126. High expression of this miRNA corre-
lated with decreased CR rates and shortened OS. Treatment with nanoparticle-based antago-
nist of miRNA-126 results in strong anti-leukemic effects in murine leukemia models and 
chemo-sensitizing effects of cytarabine and idarubicin in AML cell lines.
Recently determined miRNAs predict the prognosis of AML. From the amount of miRNAs 
were indicated miRNAs, which expression is dysregulated in patients with poor prognosis 
of AML. miRNA-107, miRNA-155, miRNA-25, miRNA-29b and miRNA-196a are associated 
with short OS of patients. The worse prognostic marker was miRNA-25 expression dysregu-
lation [76].
3. Conclusion
The normal bone marrow stressor or injury factors act as dysregulators of epigenetic and 
genetic program of hematopoietic stem cells, which is due to downregulation of separated 
sncRNAs and upregulation of other sncRNAs. These events result in the development of 
imbalance of regulating cell program and consequent transformation of normal hematopoi-
etic cells into leukemic. In this case, genotypic and phenotypic markers of pathologic cells 
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are changing. These cells change its functions. They lose possibility to normal lifecycle: to 
differentiation, maturation and death. As a consequence, leukemic cells produce abnormal 
proteins and express particular palette of sncRNAs, which worsens the negative impact into 
development of AML.
The chemotherapy may change expression map of sncRNAs in the advantageous or in the 
disadvantageous position. The study of this map may be useful tool for hematologists and 
hemato-oncologists in the diagnostic of course, efficacy and prognosis of AML in the particu-
lar case. In the course of chemotherapy, downregulation of oncogenic sncRNAs and inducing 
of tumor suppressor sncRNAs associates with favorable prognosis of disease. On the con-
trary, inhibition of sncRNAs with tumor suppressive properties and high expression of onco-
genic sncRNAs due to unfavorable prognosis of AML.
Reversing of changed epigenetic program of cells and its supporting may be the novel tool 
for the treatment of different hematological malignancies even which have poor prognosis. 
Treatment with anti-oncomiRNAs and inducing of producing, biogenesis and maturation 
of miRNAs with tumor suppressive properties may be new therapeutic benefit in complex 
therapy of AML. However, limitations to this treatment modality include the instability of 
free-floating anti-miRNAs in the plasma and their vulnerability to breakdown by nucleases, 
nonspecific tissue uptake and renal clearance. These limitations can be overcome by nanopar-
ticle-based delivery of the anti-miRNAs to target tissues.
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